Health-claim substantiation (EFSA 13/14)

01Overview and value chain#

Markers EC: EU Regulation 1924/2006 (Nutrition and Health Claims) | OECD: food-systems, cross-cutting | Regulator: FDA (USA)

Health-claim substantiation prepares the scientific and clinical evidence dossier required to support a food, supplement, or nutraceutical health claim under the EU’s Article 13/14 framework (EFSA Regulation 1924/2006) or equivalent national health-claim regimes. A health claim — “supports immune function,” “reduces cholesterol absorption” — cannot be marketed in the EU without a substantiated, EFSA-reviewed evidence base, making this a genuine regulatory-compliance service distinct from general food-safety testing. The confirmed vendor base spans a range of positioning: a large generic testing/certification conglomerate with nutrition-science capability, a dedicated EU health-claim regulatory consultancy, and a North American firm spanning regulatory strategy through clinical trial execution.

The key directions of health-claim substantiation are:

1. Article 13/14 dossier preparation: compiling the scientific evidence base required for EFSA’s general-function (Article 13) or disease-risk-reduction (Article 14) health-claim categories.
2. Clinical trial design and execution for claim support: running the human clinical studies needed to generate claim-supporting evidence where existing literature is insufficient.
3. Regulatory strategy from concept to filing: advising a client from initial claim concept through the full EFSA submission and review process.
4. Cross-jurisdictional claim harmonization: adapting a substantiated claim for multiple regulatory regimes (EU, US FDA, other national frameworks) from a shared evidence base.

Sectoral value chain#

[Claim concept development] ──> [Evidence gap analysis] ──> [Clinical trial execution] ──> [Dossier compilation]
                                                                        │
                                                              (EFSA submission)
                                                                        │
                                                                        ▼
[Claim market authorization] <─── [Regulatory review response] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• Systematic literature review methodology: structured evidence-review techniques required to assess a claim’s existing scientific support.
• Clinical trial design for regulatory claims: trial design specifically oriented toward generating EFSA-acceptable evidence rather than general research publication.
• Regulatory dossier formatting expertise: the specific documentation and formatting knowledge required for an EFSA-compliant submission.

02US#

The US has one confirmed vendor spanning regulatory strategy through clinical execution.

Regulatory strategy to clinical execution, certification and consumer trust#

• Nutrasource (SGS Nutrasource): confirmed via its own domain’s case coverage of advancing CBD innovation through regulatory-strategy-to-clinical-execution work with DSM-Firmenich, and independent Nutritional Outlook coverage of how the SGS Nutrasource brand serves the industry through certifications, clinical trials, and consumer-trust practice.

03CN#

No Chinese vendor with a dedicated, confirmed health-claim-substantiation practice was found on a live screen.

No confirmed dedicated vendor#

• Market context: this article found no Chinese company with confirmed, on-topic evidence of a dedicated EFSA-style health-claim-substantiation practice.
• Reopen condition: if a Chinese vendor selling confirmed health-claim-substantiation services surfaces on a future screen, this section should be revised and the company added to the table.

04EU#

The EU has two confirmed vendors, spanning a large generic testing/certification conglomerate and a dedicated regulatory consultancy.

Nutrition-science testing capability, dedicated EU health-claim consulting#

• Intertek (UK): a large testing, inspection, and certification conglomerate with confirmed nutrition-science and EFSA-relevant capability, evidenced via its own LinkedIn coverage referencing nutrition science and EFSA specifically alongside independent food/pharma-law coverage of health-claims regulation.
• Care Europe (Belgium): confirmed via its own blog coverage of nutraceutical regulatory consulting for EU market entry, alongside a third-party regulatory-services page referencing its health-claims work — a food-regulatory consultancy broader than health-claims exclusively, but with genuine claim-substantiation-relevant work documented.

05Leading companies and research institutes#

06Tech stack and innovations#

The category’s core capability is scientific and regulatory expertise applied to evidence generation and dossier preparation, rather than a physical technology.

1. Regulatory-strategy-to-clinical-execution integration:
   • Nutrasource’s documented work with DSM-Firmenich spans from initial regulatory strategy through actual clinical trial execution, reflecting a full-service model rather than dossier-writing alone.
2. Large-conglomerate nutrition-science capability:
   • Intertek’s scale as a testing/certification conglomerate gives it broad laboratory and scientific-review capacity applicable to health-claim substantiation, distinct from a boutique regulatory consultancy’s narrower focus.
3. Dedicated EU market-entry regulatory strategy:
   • Care Europe’s positioning specifically around EU nutraceutical market entry reflects the jurisdiction-specific expertise health-claim substantiation requires, since EFSA’s Article 13/14 framework is distinct from other national regimes.

07Value chains and production pipelines#

Industrial pipeline of an EFSA health-claim dossier (EU Regulation 1924/2006)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Claim concept development │ ───> │ 2. Evidence gap analysis   │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Dossier compilation      │ <─── │ 3. Clinical trial execution │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. EFSA submission/review response │ ───> │ 6. Claim market authorization │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Claim concept development

The client and consultant define the specific health claim to be substantiated, tied to the product’s formulation and marketing goals.

Stage 2: Evidence gap analysis

Existing scientific literature is reviewed against the claim to identify what evidence already exists and what gaps remain.

Stage 3: Clinical trial execution

Where evidence gaps exist, human clinical studies are designed and run specifically to generate claim-supporting data.

Stage 4: Dossier compilation

The full scientific and clinical evidence base is compiled into a formatted dossier meeting EFSA’s Article 13/14 submission requirements.

Stage 5: EFSA submission/review response

The dossier is submitted to EFSA, and the consultancy responds to any scientific review questions raised during assessment.

Stage 6: Claim market authorization

Once authorized, the claim can be used in EU product marketing, completing the regulatory pathway from concept to market.